| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | Recombinant human RORC protein was used as the immunogen for the RORC antibody. The epitope has been found to be with amino acids 1-50. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
This MAb recognizes a protein of 63kDa, identified as ROR-C. Its epitope maps in between aa1-50. The nuclear orphan receptors ROR and ROR are members of the nuclear hormone receptor superfamily. Members of this family act by directly associating with DNA sequences known as hormone response elements (HREs) and typically bind DNA as either homo- or heterodimers. RORalpha and RORgamma are unique in that they bind DNA as monomers. RORalpha has multiple isoforms that share common DNA and putative ligand-binding domains, but differ in their amino terminal domains, which are generated by alternative RNA processing. RORgamma comprises a 560 amino acid protein that shares 50% amino acid identity with RORalpha and is most highly expressed in skeletal muscle. Although these proteins are considered orphan receptors, due to a lack of defined ligands, experimental evidence has shown that melatonin may be the natural ligand for these nuclear receptors.
This anti-RORC antibody is supplied as Purified (Mouse, Monoclonal (mouse origin), clone RORC/2942, Mouse IgG2a, kappa, Unconjugated) and is designed to support common target-detection workflows after the on-page specifications.
Key elements and design rationale
- Target: RORC
- Format: Purified
- Species reactivity: Human
- Applications (listed): ELISA
- Conjugate: Unconjugated
- Clone and antibody class: Monoclonal (mouse origin), clone RORC/2942, Mouse IgG2a, kappa
Because antibody performance can depend on epitope context, sample preparation, and biological state, interpret signals using appropriate controls and orthogonal evidence when possible.
Biological background
RORC is referenced in public gene/protein resources (e.g., UniProt and NCBI Gene), which provide curated names/synonyms, protein features, and pathway context. When designing assays, consider potential isoforms, post-translational modifications, and cell-type specific expression that may influence observed signal.
Research relevance and current trends
- Profiling RORC expression across model systems, perturbations, and time points to support mechanistic hypotheses.
- Combining antibody-based detection with multi-omics or imaging readouts to link RORC signal with phenotype.
- Using well-matched controls (isotype controls, genetic perturbations, or independent reagents) to strengthen interpretation of target-associated signal.
Common research applications
- ELISA
Use the listed applications as a starting point and tailor experimental design to your sample type and readout requirements.
Notes for experimental interpretation
- Specificity considerations: closely related family members, isoforms, or PTMs can affect apparent specificity; confirm with independent approaches when critical.
- Controls: include negative controls and, when feasible, genetic or pharmacologic perturbations to support target attribution in your system.
- Species and sample context: differences in sequence, expression, fixation, or extraction conditions can change signal behavior across models.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.